{
    "clinical_study": {
        "@rank": "120936", 
        "acronym": "IMAGER", 
        "arm_group": [
            {
                "arm_group_label": "Control arm", 
                "arm_group_type": "Other", 
                "description": "5-ALA fluorescence guided surgery in patients with contrast enhancing tumors."
            }, 
            {
                "arm_group_label": "Interventional arm", 
                "arm_group_type": "Other", 
                "description": "5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that the rate of radiologically complete resections of\n      contrast-enhancing brain tumors following surgeries aided by use of 5-ALA induced\n      fluorescence guidance and use of an intraoperative ultra-low field MRI is higher compared to\n      surgeries aided by 5-ALA induced fluorescene alone."
        }, 
        "brief_title": "Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Malignant Neoplasm of Nervous System", 
            "Glioma", 
            "Glioblastoma", 
            "Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Neoplasms", 
                "Glioblastoma", 
                "Glioma", 
                "Neoplasm Metastasis", 
                "Nervous System Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patient (> 18 years) able to give informed consent\n\n          -  primary supratentorial intra-axial brain tumor exhibiting contrast enhancement\n             suspected to be malignant glioma\n\n          -  tumor must be deemed completely resectable by neurosurgeon\n\n          -  diagnostic MRI\n\n        Exclusion Criteria:\n\n          -  patient unable or unwilling to give informed consent\n\n          -  infratentorial tumor location\n\n          -  tumor location in or near eloquent areas\n\n          -  multifocal tumor\n\n          -  existance of contraindications to undergo MRI examination\n\n          -  previous surgical treatment for an intraaxial brain tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798771", 
            "org_study_id": "JohannWGUH_IMAGER", 
            "secondary_id": "206/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Interventional arm", 
                "description": "5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.", 
                "intervention_name": "Interventional arm", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "5-ALA", 
                    "5-Aminolevulinic acid hydrochloride"
                ]
            }, 
            {
                "arm_group_label": "Control arm", 
                "description": "5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.", 
                "intervention_name": "Control arm", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "5-ALA", 
                    "5-Aminolevulinic acid hydrochloride"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aminolevulinic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "primary brain tumor", 
            "malignant glioma", 
            "intraoperative MRI", 
            "5-ALA"
        ], 
        "lastchanged_date": "February 25, 2013", 
        "link": {
            "description": "Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011 Oct;12(11):997-1003. Epub 2011 Aug 23.", 
            "url": "http://www.sciencedirect.com/science/article/pii/S1470204511701966"
        }, 
        "location": {
            "contact": {
                "email": "c.senft@med.uni-frankfurt.de", 
                "last_name": "Christian Senft, MD PhD", 
                "phone": "069-6301", 
                "phone_ext": "5939"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt am Main", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60528"
                }, 
                "name": "Klinik f\u00fcr Neurochirurgie Johann Wolfgang Goethe University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery", 
        "other_outcome": {
            "description": "The change of NIHSS (The NIH Stroke Scale) score is an other pre-specified outcome measure", 
            "measure": "NIHSS", 
            "safety_issue": "Yes", 
            "time_frame": "5 days following surgery"
        }, 
        "overall_contact": {
            "email": "c.senft@med.uni-frankfurt.de", 
            "last_name": "Christian Senft, MD PhD", 
            "phone": "069-6301", 
            "phone_ext": "5939"
        }, 
        "overall_official": {
            "affiliation": "Dept. of Neurosurgery, Johann Wolfgang Goethe University Hospital", 
            "last_name": "Christian Senft, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the rate of complete resections according to early postoperative MRI.", 
            "measure": "Extent of Resection", 
            "safety_issue": "No", 
            "time_frame": "Early postoperative MRI within 72 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798771"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "investigator_full_name": "Dr. Christian Senft", 
            "investigator_title": "PD Dr. med. Christian Senft", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary endpoint is the volumetric extent of resection as determined by direct comparison of preoperative and early postoperative tumor volumes.", 
                "measure": "Volumetric extent of resection", 
                "safety_issue": "No", 
                "time_frame": "Early postoperative MRI within 72hrs"
            }, 
            {
                "description": "Secondary endpoint is the rate of subjects with progression-free survival (PFS) 6 months after tumor resection", 
                "measure": "PFS 6", 
                "safety_issue": "No", 
                "time_frame": "6 months following surgery"
            }, 
            {
                "description": "Secondary endpoint is the rate of subjects with progression-free survival (PFS) 12 months after tumor resection", 
                "measure": "PFS 12", 
                "safety_issue": "No", 
                "time_frame": "12 months following surgery"
            }, 
            {
                "description": "Patient quality of life at 6 and 12 months following surgery is a secondary endpoint", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months/12 months"
            }
        ], 
        "source": "Johann Wolfgang Goethe University Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johann Wolfgang Goethe University Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}